Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 2Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 993Neoplasms 852Carcinoma, Non-Small-Cell Lung 845Prostatic Neoplasms 528Neoplasm Metastasis 501Leukemia, Myeloid, Acute 489Melanoma 456Colorectal Neoplasms 447Multiple Myeloma 441Lung Neoplasms 422Pancreatic Neoplasms 353Recurrence 350Lymphoma 350Ovarian Neoplasms 341Lymphoma, Non-Hodgkin 329Leukemia 324Leukemia, Lymphocytic, Chronic, B-Cell 302Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Carcinoma, Renal Cell 256Head and Neck Neoplasms 246Brain Neoplasms 245Carcinoma, Hepatocellular 234Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Myelodysplastic Syndromes 231Lymphoma, Large B-Cell, Diffuse 228Lymphoma, Follicular 219Colonic Neoplasms 191Stomach Neoplasms 182Rectal Neoplasms 175

Interventions

Paclitaxel 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interventional × Advanced Endometrial Cancer × Clear all
NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
71 enrolled
GynecologicSarcoma

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡